Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 0.00 |
| Open | 26.25 |
| Bid | 27.00 x 40000 |
| Ask | 27.40 x 40000 |
| Day's range | 26.25 - 26.25 |
| 52-week range | 23.80 - 32.76 |
| Volume | |
| Avg. volume | 22,929 |
| Market cap | 44.36B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | 44.49 |
| EPS (TTM) | 0.59 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | 1.26 (4.87%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
Business WireTakeda Announces New Assignments of Directors
OSAKA, Japan, June 26, 2024--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today.
ZacksFDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Business WireTakeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
OSAKA, Japan & CAMBRIDGE, Mass., June 24, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1
